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Abstract Lipoprotein lipase (LPL) plays a central role in 
triglyceride metabolism, regulating the catabolism of triglyc- 
eride-rich lipoprotein particles. LPL performs its hydrolytic ac- 
tion attached to heparan sulfate proteoglycans at the luminal 
surface of capillary endothelial cells. We have assessed the effect 
of the Asn TM ---)Ser (N291S) substitution found in LPL gene from 
a human hyperlipemic patient. Our results showed that both the 
wild-type (WT) and N291S hLPL expressed in COS1 cells were 
secreted to the extracellular medium, and presented similar intra- 
cellular distibution patterns. Furthermore, heparin-Sepharose af- 
finity chromatography assays revealed normal heparin affinity of 
the N291S hLPL. In addition, both the mutant and the WT 
protein bound to the surface of human fibroblasts and untrans- 
fected COS1 cells. Interestingly, disminished LPL specific activ- 
ity was observed in the extracellular medium from mutant ex- 
pressing cells. Therefore the lack of normal LPL activity in 
patients harbouring such a mutation could be the cause of their 
hyperlipemic disorder. 
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1. Introduction 
Lipoprotein lipase (LPL) is responsible for the hydrolysis of 
core triglycerides of circulating chylomicrons and very low den- 
sity lipoproteins (VLDL). The active enzyme is a non-covalent 
homodimer [1], is synthesized and secreted in several parenchy- 
real cells including the adipocyte, myocyte and those of lactat- 
ing mammary gland [24]. After secretion LPL binds with high 
affinity to heparan sulfate proteoglycans at the surface of secre- 
tory cells [5] and it is anchored to similar receptors on the 
capillary endothelial cells, which do not themselves synthesize 
LPL [6,7]. 
LPL has high affinity for heparin, which is provided by 
several amino acid clusters in the enzyme that confer elec- 
trostatical potential. Cluster 1: ArgZ63-Arg279-LysZS°-Arg 282 and 
cluster 2: Arg294-Lys296-Arg297-Lys3°° contain two hypothetical 
heparin-binding regions whose sequences form part of an irreg- 
ular surface loop at the junction of the N-terminal and C- 
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terminal domains. A third heparin binding domain is found 
between residues 148 and 152 (cluster 3). This region is con- 
tained in a surface loop located close to clusters 1 and 2, and 
could therefore contribute to heparin binding [8]. Recently, 
site-directed mutagenesis studies [9] have confirmed that the 
region including the residues from 220 to 330 in the N-terminal 
domain of LPL is crucial for heparin affinity. Other studies [10] 
have identified further heparin binding determinants in the 
protein. These studies uggest that both LPL tertiary structure 
and consensus sequences are essential to the heparin affinity of 
the enzyme. 
Lipoprotein lipase deficiency is characterized by hyperchylo- 
micronemia, which often develops to lipemia retinalis, pan- 
creatitis, and eruptive xanthomas [11]. A number of genetic 
defects within the coding region of the LPL gene, leading to 
catalytically inactive protein, have been reported [12]. Many of 
the defects have been found in the middle portion of the LPL 
molecule, a highly conserved region among species and in the 
lipase gene family [13,14]. In a screening study of hypertriglyc- 
eridemic human patients we investigated the genetic back- 
ground of a patient (J.K.) who presented Von Gerke's syn- 
drome associated with a disorder in the glycogen metabolism. 
His plasma was milky and had half of normal LPL activity. 
Analysis of the coding sequence of the LPL gene of this patient 
using PCR-SSCP revealed the presence of a single base substi- 
tution, in heterozygous form, predicted to replace Asp TM by a 
serine in the mature LPL protein. Since the Asn 291 is located 
between clusters 1 and 2, which are known to be involved in 
LPL heparin binding [8], we postulated that this mutation may 
reduce LPL affinity for heparin. Furthermore, Reymer et al. 
[15] and Gehrisch et al. [16] reported that this mutation 
(Asn291---~Ser) was found, with relatively high frequency, 
among patients with Familial Combined Hyperlipoproteinemia 
(FCH) or Familial Dyslipemia (FDL). Reymer et al. [17] also 
reported association of the allele N291S with premature athero- 
sclerosis. It was thus suggested that this allele could be a poly- 
morphism in some populations and might be one of the genetic 
factors involved in the development of FCH or FDL. 
In order to determine the contribution of the Asn 291 residue 
to the affinity of LPL for heparin and to its catalytic activity, 
we produced and characterized the N291S hLPL mutant pro- 
tein by site-directed mutagenesis and expression i  COS1 cells. 
We expressed the wild-type (WT hLPL) and the mutant cDNAs 
in COS1 cells by transient ransfection, and we searched for 
differences between these two proteins. 
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2. Matherials and methods 
2.1. LPL mutagenesis 
The full-length uman LPL (hLPL) cDNA clone was isolated by 
reverse transcription ofRNA from THP-1 cells (ATCC TIB202) differ- 
entiated with phorbol esters and dexamethasone [18], followed by PCR 
amplification. It was sequenced in its entirely and shown to encode the 
wild-type enzyme. Site-directed mutagenesis of the full-length uman 
LPL cDNA cloned into the EcoRI site of PTZ18U vector was carried 
out according to the method of Kunkel et al. [19] using a site-directed 
mutagenesis kit from Bio-Rad (Bio-Rad, Richmond, CA, USA). The 
oligonucleotide primer (5'GC TAT GAG ATC TCC AAA GTC A3') 
used for mutagenensis (Eurogentec, Belgium) contained the codon 291 
substitution TCC (Asn) for AAT (Ser). This substitution created aBgIII 
restriction site, which was confirmed by digestion with BglII (Pharma- 
cia, Brussels, Belgium) and by sequencing. For expression in COS 1 
cells, the wild type and the mutant cDNAs were cloned into the EcoRI 
site of the expression vector pCAGGS [20,2l], which contains the fl- 
actin promoter and the cytomegalovirus enhancer. 
2.2. Cell culture and tramfection 
COSI cells were cultured in Dulbecco's Modified Eagle's Medium 
(DMEM) (Whittaker, Walkersville, MD, USA) supplemented with 
10% fetal bovine serum (Whittaker), antibiotics and glutamine (2 mM) 
(Sigma, St. Louis, MO, USA). For immunofluorescence experiments, 
cells were cultured in 6 multi-well dishes containing lass coverslips. 
For blotting and other experiments, cells were cultured in 10 cm plates 
containing 10 ml of medium. Cells at 80% of confluence were trans- 
fected with 2.5/~g of DNA by the DEAE-Dextran method [22]. All cells 
were tested 48 h after transfection. 
2.3. Heparin treatment and cell lysis 
For heparin treatment transfected cells were incubated with medium 
containing 10 U/ml of heparin (Sigma) after transfection. To obtain the 
cell lysates, cells were washed (twice) in cold PBS 48 h after transfection 
and then lysed in the buffer A (1% Triton X-100, 1 mM PMSF, 5/lg/ml 
leupeptin, 2 mM EDTA, 0.5 ¢tg/ml aprotinin (Sigma) in PBS). The 
lysates were scraped from the dishes and passed through asyringe (with 
a 22-gauge needle) and then being rapidly frozen in liquid nitrogen. 
Then they were sonicated for 30 s at maximum power and centrifuged 
at 12,000 x g for 10 min at 4°C in a Heraeus-Sepatech Biofuge. The 
supernatant was considered as the cell extract. 
2.4. Western blotting assays 
Cell extracts and media of transfected cells were removed from the 
culture dishes and loaded into SDS-polyacrylamide g ls. Gels were 
blotted to nitrocellulose at 15 V for 1.5 h using the semi-dry system of 
Bio-Rad. The nitrocellulose membranes (Cellulosenitrat BA85 from 
Schleicher and Schuell, Dassel. Germany) were blocked with 3% pow- 
dered milk in PBS and LPL was detected with a monoclonal antibody 
against bovine LPL (5D2) (Oncogene, NY, USA) and a secondary 
peroxidase-conjugated anti-mouse antibody at dilution (1:2000) (Da- 
kopatts, Glostrup. Denmark). The blot was developed with the ECL 
system from Amersham (Bucks, United Kingdom). 
2.5. Heparin-Sepharose chromatography, ELISA and activity assays 
Heparin-Sepharose affinity chromatography was performed as de- 
scribed by ()stlund-Lindqvist and Boberg [23] using the FPLC system 
from Pharmacia. The column was equilibrated with Robinson buffer 
(10 mM Tris-HCl, pH 7.2, 20% w/v glycerol, 0.1% w/v Triton X-100) 
and chromatography was performed at a flow rate of 0.5 ml/min. 30 
fractions of 1 ml were collected. LPL was eluted from the column using 
a linear gradient of NaCI. 
LPL mass was measured in the fractions from heparin-Sepharose 
chromatography and media using solid-phase sandwich ELISA with 
polyclonal chicken antibodies (from Dr. Bengtsson-Olivecrona, Umegt, 
Sweden) for coating and the 5D2 monoclonal antibody for detection 
as described by Vilella et al. [24]. Absorbance at 492 nm was measured 
and used as a relative value to plot the heparin-Sepharose chromato- 
grams and to calculate specific activities. 
Lipoprotein lipase activity in medium was determined as described 
by Ramirez et al. [25]. One milliunit of lipolytic activity represents 
release of 1 nmol fatty acid/min. 
2.6. Binding assays and immunofluorescence microscopy 
LPL binding assays were performed by placing glass coverslips with 
a subconfluent monolayer of human fibroblasts in a 10 cm dish with 
COS1 cells transfected with either the WT hLPL or the N291S hLPL. 
The coverslips were placed immediately after the transfection process 
and both growing cell lines shared the same culture medium, in which 
the LPL secreted by the transfected cells could bind to the surface of 
the fibroblasts added. LPL binding was then detected by immunofluo- 
rescence. 
For immunofluorescence labeling, cells grown on glass coverslips 
were rinsed briefly in PBS, fixed with methanol (-20°C) for 2 min, 
washed twice in PBS and processed. As primary antibody, we used the 
monoclonal antibody anti bovine LPL (5D2) (Oncogene). To visualize 
the primary antibody, we used a secondary RITC-conjugated goat 
anti-mouse (Boehringer-Mannheim, Mannheim, Germany). All anti- 
bodies were diluted in PBS containing 0.5% of BSA (Sigma). Primary 
antibodies were applied for 45 min at 37°C, followed by a 10 min wash 
in PBS, then 45 rain incubation at 37°C with the secondary antibody, 
followed by a final wash of 10 min in PBS. Finally, coverslips were 
labeled with the nuclear stain Hoechst 33342 (Sigma) diluted in PBS. 
The coverslips were mounted with immunofluorescence m dium (ICN 
Biomedicals Inc., Costa Mesa, CA, USA) and viewed with 40 x or 
100 x objective using a Reichert Jung Polyvar II microscope quipped 
with epifluorescence illumination. Photographic exposures were made 
on Kodak Tmax 400 film. 
3. Results 
To study the effects of the N291S substitution on LPL proc- 
essing, affinity for heparin and catalytic activity, we expressed 
either the WT or the variant LPL cDNAs in COS1 cells by 
transient transfection using the DEAE-dextran chloroquine 
method. Assays were carried out 48 h following transfection. 
By RNA slot blot and hybridization with [32p]hLPL labelled 
probe we found equal expression of both constructs (not 
shown). Intracellular LPL was detected by Western blotting of 
cell extracts, and in both cases (the WT and the N291S hLPL) 
a single band with the same molecular weight (58 kDa) similar 
to bovine LPL (55 kDa) was identified using the monoclonal  
5D2 ant ibody (Fig. 1A). This result indicates that similar high 
levels of expression were accomplished when transfecting either 
with the wild-type or with the mutant  protein. Western blot 
experiments also revealed high amounts of LPL in culture 
media upon transfection with either the variant or WT LPL, 
indicating that both proteins were equally well secreted to the 
medium (Fig. 1B). 
The efficiency with which heparin released the N291 S protein 
from cells was next determined. Cells transfected with either 
N291S or wild type were treated with 10 U/ml of heparin for 
24 h (at 48 h after transfection). Slot blot assays of culture 
media using the 5D2 antibody showed similar increasess in LPL 
after treatment with heparin (Fig. 2A). We found increased 
presence of LPL in heparin-treated cells in both cases, indicat- 
ing the same stimulating effect. Involvement of the Asn TM in the 
affinity of the LPL for heparin was investigated using heparin- 
sepharose affinity chromatography. Our results indicated that 
both  the N291S and the WT hLPL  presented the same heparin 
affinity (Fig. 2B). The molarity of LPL elution was around 0.6 
M NaC1 for the monomeric LPL and 1 M NaC1 for the dimeric 
LPL in the case of both mutant  and the WT hLPL. As expected, 
most of the LPL in the media was found in its monomeric form 
(in both the WT hLPL and the mutant  hLPL)  since it is known 
that LPL monomerizes after incubation at 37°C. 
Immunofluorescence microscopy was used to determine the 
intracellular distribution pattern of LPL in mutant-expressing 
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Fig. 1. Western blot analysis of LPL protein in cell extracts and media in wild-type and N291S COS 1 transfected cells. Equal amounts of vector (NT), 
wild-type (lane 1) and N291S mutant hLPL expressing cell extracts (A) or medium (B) were separated by SDS-PAGE electrophoresis. 0.5 pg of bovine 
LPL (bLPL) was included as control (arrowhead, 55 kDa). The gels were blotted into nitrocellulose and LPL was detected using the 5D2 monoclonal 
antibody, revealing a single band of 58 kDa (arrow). 
cells. As expected from the secretion studies, the intracellular 
LPL detected with the 5D2 antibody showed the same distribu- 
tion pattern for both the wild type and the mutant expressed 
LPL. The immunoreactivity (Fig. 3A,B) seemed to be located 
mostly in the Golgi (see arrow) and spread throughout he 
cytoplasm in the ER but never showed an intracellular pattern 
of retention, which was reported previously for N43A ex- 
pressed LPL mutant proteins [26]. 
Recently, it has been demonstrated that LPL binds with high 
affinity to heparan sulfate proteoglycans on the surface of skin 
human fibroblasts following an ordered regular distribution 
pattern. This pattern mostly reflects the arrangement of these 
cellular receptors on the cell surface [27]. With the purpose of 
determinating whether the mutant N291S hLPL was capable 
of binding to the cell surface of human skin fibroblasts and to 
untransfected COS1 cells, we performed binding assays by 
placing glass coverslips with a fibroblast culture into dishes of 
transfected COS1 cells (WT and mutant expressing cells). Im- 
munofluorescence studies were then carried out by incubating 
coverslips with the 5D2 monoclonal antibody. The im- 
munofluorescent images demonstrated that both the WT and 
the mutant hLPL proteins were clearly able to bind to the cell 
surface of both the human skin fibroblasts (Fig. 3C,D) and 
untransfected COSI cells (Fig. 3E,F). This result indicated that 
the affinity for heparan sulfate receptors remained unaltered by 
the mutation N291S. Up to this point we had not been able to 
detect differences between the molecular behaviour of the WT 
and the N291S hLPL. 
LPL activity and mass in media of N291S- and WT hLPL- 
expressing cells were measured. The results (Fig. 4) indicate 
that the specific activity of mutant LPL in the medium was 
approximately 60% of the secreted WT hLPL. 
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Fig. 2. Slot blot analysis of culture media from wild-type (WT) and N291S hLPL transfected cells upon heparin treatment (A). Transfected cells with 
wild-type or mutant cDNAs were incubated with (2) or without (1) medium containing 10 U/ml of heparin for 48 h. Media was collected and subjected 
to slot blot analysis using 5D2 monoclonal antibody. Heparin-Sepharose chromatography assay of culture media from WT and mutant expressing 
COS 1 cells (B). Media from WT and N291S hLPL transfected cells were injected in a heparin Sepharose chromatography column to check the heparin 
affinity of both expressed proteins. The FPLC system from Pharmacia was used and 30 fractions of 1 ml were collected after elution with a NaCI 
gradient. The fractions were quantified for LPL using an ELISA assay with polyclonal rabbit immunoglobulins for coating and the 5D2 monoclonal 
antibody for detection. 
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Fig. 3. Intracellular distribution of the wild-type (WT) and the N291 S hLPL in COS 1 cells (A,B). Immunofluorescent de ection of LPL on transfected 
COS 1 cells grown on glass coverslips. (A) shows the LPL immunostaining of WT hLPL transfected cells; (B) shows the LPL distribution pattern 
of N291S hLPL expressing cells. The monoclonal 5D2 antibody was used as the primary antibody and anti-mouse FITC immunoglobulins a  the 
secondary antibody. Immunofluorescent de ection of the WT and mutant hLPL on the surface of human fibroblasts (C,D) and non-transfected COS 1 
cells from the same culture (E,F). Glass coverslips of cultured transfected COS1 cells as well as glass coverslips with subconfiuent human skin 
fibroblasts placed in the transfected COSI cells culture dish for 24 h were immunolabeled with the 5D2 monoclonal antibody and the secondary 
anti-mouse FITC-conjugated antibody. WT (C) and mutant (D) hLPL labeling on the surface of human fibroblast sharing culture medium with the 
transfected COS1 cells is shown. WT (E) and mutant hLPL (F) labeling (arrow) on surface of non-transfected COS1 cells. Bars -- 30 pm. 
4. Discussion 
In this study we report effects of the mutat ion N291S in the 
human l ipoprotein lipase molecule. We created the N291S mu- 
tation in the human LPL cDNA by site-directed mutagenesis 
and we transiently expressed the WT hLPL and the mutant  
hLPL  in COS1 cells. We found out that the N291S hLPL was 
normally synthesized and distributed inside the cell, and nor- 
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Fig. 4. LPL mass in medium (expressed in OD units at 492 nm) was 
measured inthe case of the wild-type (WT) and mutant N291S express- 
ing cells as described insection 2. LPL activity (expressed in mU/ml of 
medium) of the same medium was assayed, and LPL specific activity 
was expressed asmU of LPL lipolytic activity per OD unit at 492 nm. 
In all cases the activity and specific activity values of media from 
non-transfected COS 1 cells (NT) and N291S hLPL expressing cells are 
referred to the level of the WThLPL considered as 100% (n = 4) 
mally secreted to the extracellular medium. In addition we 
observed that it had normal affinity for heparin and was capa- 
ble of binding to surface heparan sulfate receptors of untrans- 
fected COS-1 cells and human fibroblasts. However, the mu- 
tant enzyme presented 42% less specific catalytic activity than 
the WT hLPL 
Extracellular matrix glycosaminoglycans regulate a number 
of metabolic processses [28] and the binding of LPL on the 
extracellular matrix is well documented [29]. For example, LPL 
is bound to the luminal side of the endothelial cell wall through 
glycosaminoglycans. Theelectrostatic nature of this interaction 
is provided by the heavily negatively charged regions of hepa- 
rin-like polysaccharides and the positively charged regions on 
the LPL surface. The maximum positive lectrostatic potential 
in LPL is constituted by four positively charged clusters: Arg 263- 
Arg279-Lys28°-Arg 2s2 (cluster 1), Arg294-Lys296-Arg297-Lys3°° 
(cluster 2), residues from the 248 to the 152 (cluster 3), and 
Lys319-Lys4°3-Arg4°5-Lys4°7-Lys414-Lys j5 (cluster 4). Among 
them, only clusters 1 and 2 have been found to be involved in 
heparin binding [10]. The mutation of Asn TM to Ser which was 
found in J.K., a patient with the Von Gerke's disease, and that 
has been found with high frequency in FCH or FDL affected 
populations, is situated between these two clusters known to be 
crucial for LPL heparin binding. The aim of our work was to 
elucidate the potential role of Asn TM in LPL affinity for hepa- 
rin. Our results indicate that this residue was not a determinant 
for heparin binding, since the N291S hLPL expressed in COS1 
ceils had normal affinity for this molecule. A tridimentional 
molecular model of LPL based on the homology with the pan- 
creatic lipase X-ray structure was proposed by van Tilbeurgh 
et al. [8]. According to this model, the heparin binding consen- 
sus sequences found in clusters 1 and 2 are close to each other 
in the folded LPL molecule. These two clusters are part of an 
irregular surface loop at the junction of the N- and C-terminal 
domains of LPL. Since Asn TM, found between these two clus- 
ters, does not affect heparin binding, we hypothesize that this 
neutral residue might remain hidden and not taking part in the 
loop exposed to the surface. 
After the completion of our studies, Reymer et al. [15] and 
also Gehrisch et al. [16] reported at the International Athero- 
sclerosis Congress, Montreal (1994) that the frequency of the 
N291S substitution, in the heterozygous state, was almost five 
times higher in FCH patients than in controls (9.3% vs. 1.9%, 
and more than five times in FDL patients (9.7% vs. 1.9%). 
Reymer et al. [17] also described a high frequency of N291S in 
population with premature atherosclerosis (5.2% vs. 1.8% of 
controls) Reymer et al. [15] also performed in vitro mutagenesis 
experiments, which revealed that the mutant N291S hLPL pre- 
sented normal heparin affinity but reduced LPL activity. Fur- 
thermore, Gehrisch et al. [16] also suggested that the N291S 
mutation influenced LPL activity. Heterozygosity for the 
Asn29~---~Ser substitution may be one of the contrib- 
uting factors in the development of Familial Combined Hyper- 
lipidemia (FCHL). Recently, heterozygosity for a mutation in 
the LPL promoter was found to be associated with FCHL [30]. 
Many missense mutations in the LPL gene have been re- 
ported to disrupt he activity of the enzyme. Among them we 
find: Gly142---~Glu [31], Asp156--*Gly [32,33], Ala194---)Thr [34], 
Arg243--~His [35], Ser244---~Thr [36], Asp25°--~Asn [37], 
Tyr262 --+ His [12,38]. Most of the residues involved in 
these mutations are known to take part in or to be adjacent to 
the catalytic domain of LPL, which consists of Ser ~32, Asp 156 
and His 241. The mutation characterized in this paper 
(Asn291--)Ser) is not associated with any residue or domain 
known to be involved in the hydrolytic apacity of the enzyme. 
This mutation was not observed among LPL deficient individ- 
uals since it does not completely abolish LPL activity. The 
reduction of activity could be due to instability of the LPL 
dimer in the culture medium. When LPL is converted from 
its dimeric form to a monomer, it loses catalytic activity [1]. 
We therefore suggest that the residue Asn TM could be 
involved in dimer formation. At present, very little is known 
about the residues and domains of LPL involved in dimeriza- 
tion. Further studies will be required to elucidate this aspect of 
LPL structure. 
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